Screener
Aurinia Pharmaceuticals AUPH Income Tax
Income Tax at other companies
Other financials
Where this comes from
Reported directly by Aurinia Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncomeTaxExpenseBenefit.
The source filing: Aurinia Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 8:16 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001600620-26-000062
| Line item | Three Months Ended / June 30, 2026 | Three Months Ended / June 30, 2025 | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|---|---|
| Interest income | 3,393 | 3,190 | 6,908 | 6,759 |
| Interest expense | (948) | (1,117) | (1,960) | (2,184) |
| Net income before income taxes | 48,786 | 22,156 | 92,711 | 46,505 |
| Income tax expense | 11,372 | 643 | 20,942 | 1,648 |
| Net income | $37,414 | $21,513 | $71,769 | $44,857 |
| Other comprehensive income: | ||||
| Unrealized loss on available-for-sale securities | (97) | (80) | (378) | (258) |
| Comprehensive income | $37,317 | $21,433 | $71,391 | $44,599 |
Item 1. Financial Statements.
FAQ
- What is Aurinia Pharmaceuticals's income tax?
- Aurinia Pharmaceuticals (AUPH) reported income tax of $11.37M in Q2 2026.
- How has Aurinia Pharmaceuticals's income tax changed year-over-year?
- Aurinia Pharmaceuticals's income tax increased by 1668.6% year-over-year, from $643K to $11.37M.
- What is the long-term trend for Aurinia Pharmaceuticals's income tax?
- Over 3 years (2021 to 2025), Aurinia Pharmaceuticals's income tax has grown at a 510.6% compound annual growth rate (CAGR), from $760K to -$173.05M.
- What does income tax mean?
- Total income tax expense (current + deferred) recognized in the income statement, representing the company's total tax obligation on pre-tax income.
Ask your AI about Aurinia Pharmaceuticals's income tax.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude